BOSTON SCIENTIFIC CORPORATION (BSX) FY2026 Q1 P&L / Income Statement

BOSTON SCIENTIFIC CORPORATION (BSX) FY2026 Q1 P&L / Income Statement

Income statement for 2026-01-01 through 2026-03-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net sales

5,203,000,000 US dollars

Cost of products sold (excluding amortization expense)

1,590,000,000 US dollars

Gross profit

3,614,000,000 US dollars

Operating expenses

2,513,000,000 US dollars

Operating income (loss)

1,101,000,000 US dollars

Other income (expense), net (calculated)

61,000,000 US dollars

Income (loss) before income taxes

1,162,000,000 US dollars

Income tax expense (benefit)

negative 176,000,000 US dollars

Net income (loss)

1,339,000,000 US dollars

Cardiac Rhythm Management - UNITED STATES

349,000,000 US dollars

Cardiac Rhythm Management - Int'l

229,000,000 US dollars

Electrophysiology - UNITED STATES

603,000,000 US dollars

Electrophysiology - Int'l

302,000,000 US dollars

Endoscopy - UNITED STATES

446,000,000 US dollars

Endoscopy - Int'l

290,000,000 US dollars

Neuromodulation - UNITED STATES

236,000,000 US dollars

Neuromodulation - Int'l

82,000,000 US dollars

Urology - UNITED STATES

465,000,000 US dollars

Urology - Int'l

182,000,000 US dollars

Interventional Cardiology & Vascular Therapies - UNITED STATES

552,000,000 US dollars

Interventional Cardiology & Vascular Therapies - Int'l

692,000,000 US dollars

Interventional Oncology & Embolization - UNITED STATES

170,000,000 US dollars

Interventional Oncology & Embolization - Int'l

99,000,000 US dollars

Watchman - UNITED STATES

462,000,000 US dollars

Watchman - Int'l

44,000,000 US dollars

Selling, general and administrative expenses

1,781,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.

Research and development expenses

516,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.

Royalty expense

12,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.

Amortization expense

232,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.

Contingent consideration net expense (benefit)

negative 30,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.

Restructuring net charges (credits)

3,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to BOSTON SCIENTIFIC CORPORATION: $1.34 B; to noncontrolling interests: −$2.00 M.

• The amounts that make up gross profit come to $3,613.00 M and gross profit is $3,614.00 M; the $1.00 M difference is within the rounding of the filed amounts.
• The amounts that make up net income come to $1,338.00 M and net income is $1,339.00 M; the $1.00 M difference is within the rounding of the filed amounts.